128746-80-5 Usage
General Description
2-BROMO-1-[4-(2-THIENYL)PHENYL]-1-ETHANONE, also known as 4-bromo-2-thiophen-2-ylacetophenone, is a chemical compound with the molecular formula C14H11BrOS. It is a yellow crystalline solid with a molecular weight of 301.2 g/mol. 2-BROMO-1-[4-(2-THIENYL)PHENYL]-1-ETHANONE is used in the synthesis of pharmaceuticals and agrochemicals, as well as in the production of various organic compounds. It is also commonly used as an intermediate in the synthesis of other chemicals and pharmaceuticals. The presence of a bromine atom and a thienyl group in its structure gives this compound interesting chemical and pharmaceutical properties, making it a valuable building block in organic synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 128746-80-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,8,7,4 and 6 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 128746-80:
(8*1)+(7*2)+(6*8)+(5*7)+(4*4)+(3*6)+(2*8)+(1*0)=155
155 % 10 = 5
So 128746-80-5 is a valid CAS Registry Number.
InChI:InChI=1/C12H9BrOS/c13-8-11(14)9-3-5-10(6-4-9)12-2-1-7-15-12/h1-7H,8H2
128746-80-5Relevant articles and documents
Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity
Kourounakis, Angeliki P.,Charitos, Christos,Rekka, Eleni A.,Kourounakis, Panos N.
supporting information; experimental part, p. 5861 - 5865 (2009/09/25)
A number of newly synthesized 2-[4-(hetero)aromatic]phenyl-2-hydroxy- tetrahydro-1,4-oxazine derivatives were found to inhibit lipid peroxidation (IC50 of the most potent was 20 μM) as well as rat squalene synthase (IC50 for most between 1-10 μM). Antidyslipidemic action was demonstrated in vivo: the most active compound decreased triglycerides, total cholesterol, and LDL-cholesterol of hyperlipidemic rats by 64, 67, and 82%, respectively, at 56 μmol/kg (ip). Most of the novel compounds are more active than the structurally related and reference biphenyl-morpholine, pointing to useful structural approaches for the design of antiatherosclerotic agents.
